IL182352A - The use of 743-et for the preparation of a cancer treatment drug and medical kits containing 743-et - Google Patents

The use of 743-et for the preparation of a cancer treatment drug and medical kits containing 743-et

Info

Publication number
IL182352A
IL182352A IL182352A IL18235207A IL182352A IL 182352 A IL182352 A IL 182352A IL 182352 A IL182352 A IL 182352A IL 18235207 A IL18235207 A IL 18235207A IL 182352 A IL182352 A IL 182352A
Authority
IL
Israel
Prior art keywords
medicament
preparation
treating cancer
kits containing
medical kits
Prior art date
Application number
IL182352A
Other languages
English (en)
Hebrew (he)
Other versions
IL182352A0 (en
Original Assignee
Ortho Biotech Products L P
Pharma Mar S A Sociedad Unipersonal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36096124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL182352(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Biotech Products L P, Pharma Mar S A Sociedad Unipersonal filed Critical Ortho Biotech Products L P
Publication of IL182352A0 publication Critical patent/IL182352A0/en
Publication of IL182352A publication Critical patent/IL182352A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL182352A 2004-10-26 2007-04-01 The use of 743-et for the preparation of a cancer treatment drug and medical kits containing 743-et IL182352A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62216304P 2004-10-26 2004-10-26
PCT/GB2005/050189 WO2006046080A2 (en) 2004-10-26 2005-10-26 Pegylated liposomal doxorubicin in combination with ecteinescidin 743

Publications (2)

Publication Number Publication Date
IL182352A0 IL182352A0 (en) 2007-07-24
IL182352A true IL182352A (en) 2016-07-31

Family

ID=36096124

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182352A IL182352A (en) 2004-10-26 2007-04-01 The use of 743-et for the preparation of a cancer treatment drug and medical kits containing 743-et

Country Status (26)

Country Link
US (1) US20090117176A1 (enExample)
EP (1) EP1827500B1 (enExample)
JP (2) JP4554684B2 (enExample)
KR (1) KR101287918B1 (enExample)
CN (1) CN101119750B (enExample)
AT (1) ATE430586T1 (enExample)
AU (1) AU2005298364B2 (enExample)
BR (1) BRPI0518250A2 (enExample)
CA (1) CA2582452C (enExample)
CY (1) CY1110329T1 (enExample)
DE (1) DE602005014380D1 (enExample)
DK (1) DK1827500T3 (enExample)
ES (1) ES2326825T3 (enExample)
HR (1) HRP20090345T1 (enExample)
IL (1) IL182352A (enExample)
MX (1) MX2007004744A (enExample)
NO (1) NO328958B1 (enExample)
NZ (1) NZ554765A (enExample)
PL (1) PL1827500T3 (enExample)
PT (1) PT1827500E (enExample)
RS (1) RS50822B (enExample)
RU (1) RU2359700C2 (enExample)
SI (1) SI1827500T1 (enExample)
UA (1) UA87877C2 (enExample)
WO (1) WO2006046080A2 (enExample)
ZA (1) ZA200703396B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US20040108086A1 (en) * 2000-11-06 2004-06-10 Naoto Takahashi Effective antitumor treatments
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
SI1689404T1 (sl) 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US8444963B2 (en) 2006-06-19 2013-05-21 John Hopkins University Tumor specific delivery of therapeutic agents via liposomase
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
RU2657835C1 (ru) * 2017-11-28 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ получения системы для доставки противоопухолевого препарата в клетки опухоли

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CZ301083B6 (cs) * 1998-04-06 2009-11-04 The Board Of Trustees Of The University Of Illinois Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2418320A1 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
ATE314084T1 (de) * 2000-10-31 2006-01-15 Pharma Mar Sa Kahalalid f formulierung
US20040108086A1 (en) * 2000-11-06 2004-06-10 Naoto Takahashi Effective antitumor treatments
HUP0303466A3 (en) * 2001-03-06 2005-02-28 Bristol Myers Squibb Company P Method and dosage form for treating tumors by administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
EP1401396A4 (en) * 2001-06-15 2009-08-05 Cornerstone Pharmaceuticals PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS WITH NANOPARTICLES FOR THE TREATMENT OF TARGET TISSUE AND CELLS
KR20050038578A (ko) * 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
AU2003253954A1 (en) * 2002-07-16 2004-02-02 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Support bra for ultrasonic breast scanner
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) * 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
RS50510B (sr) * 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
WO2007062413A2 (en) * 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
WO2007134203A2 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
RS50822B (sr) 2010-08-31
RU2359700C2 (ru) 2009-06-27
JP2009292850A (ja) 2009-12-17
WO2006046080A3 (en) 2006-10-19
AU2005298364A1 (en) 2006-05-04
CN101119750A (zh) 2008-02-06
DE602005014380D1 (de) 2009-06-18
EP1827500B1 (en) 2009-05-06
AU2005298364B2 (en) 2009-03-26
NO20072543L (no) 2007-07-13
ES2326825T3 (es) 2009-10-20
MX2007004744A (es) 2007-10-23
US20090117176A1 (en) 2009-05-07
PL1827500T3 (pl) 2009-09-30
BRPI0518250A2 (pt) 2008-11-11
CA2582452C (en) 2010-09-07
WO2006046080A2 (en) 2006-05-04
CN101119750B (zh) 2013-03-06
NO328958B1 (no) 2010-06-28
KR101287918B1 (ko) 2013-07-19
JP4554684B2 (ja) 2010-09-29
IL182352A0 (en) 2007-07-24
DK1827500T3 (da) 2009-08-31
JP2008517991A (ja) 2008-05-29
ATE430586T1 (de) 2009-05-15
HK1107766A1 (en) 2008-04-18
KR20070108135A (ko) 2007-11-08
UA87877C2 (en) 2009-08-25
SI1827500T1 (sl) 2009-10-31
WO2006046080A8 (en) 2007-07-12
EP1827500A2 (en) 2007-09-05
ZA200703396B (en) 2008-11-26
NZ554765A (en) 2010-01-29
RU2007119545A (ru) 2008-12-10
HRP20090345T1 (en) 2009-08-31
CA2582452A1 (en) 2006-05-04
PT1827500E (pt) 2009-08-05
CY1110329T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
IL182352A0 (en) The use of et-743 in the preparation of a medicament for treating cancer and medical kits containing et-743
IL273765A (en) Combinations and forms of administration of therapeutic agents and combined treatment
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
EP1586338A3 (en) The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
WO2001066123A3 (en) Composition consisting of phy906 and chemotherapeutic agents
MY164077A (en) Compositions and uses of et743 for treating cancer
IL155781A0 (en) Effective antitumor treatments
PT1689404E (pt) Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
AU2002253785A1 (en) Catheter and implants for the delivery of therapeutic agents to tissues
GB0020504D0 (en) Therapeutic method
JP2008517991A5 (enExample)
AU2001236529A1 (en) Combination therapy for cancer
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
BRPI0416019A (pt) uso de siramesina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, kit, e, método para o tratamento de cáncer
NZ516564A (en) Cancer therapy
ZA200301789B (en) Use of rhPBGD in new therapeutic methods for treating patients with acute intermittent porphyria (AIP) and other porphyric diseases.
AU2003219508A1 (en) A process for the preparation of a new medicinal combination for regression of intracranial tumors and other tumors occurring in the human body

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed